Determining the duration of therapy for patients with community-acquired pneumonia

Current Infectious Disease Reports

Volumn 15, Issue 2, 2013, Pages 191-195

  Scalera, Nikole M ^a   File Jr , Thomas M ^a  

^a SUMMA HEALTH SYSTEM   (United States)

Author keywords

Antibiotics; Antimicrobial stewardship; Community acquired pneumonia; Duration; Procalcitonin

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME; DOXYCYCLINE; GEMIFLOXACIN; KETOLIDE; MACROLIDE; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; LENGTH OF STAY; META ANALYSIS (TOPIC); MORTALITY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION;

EID: 84877920559     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0327-3     Document Type: Article

References (25)

1. File Jr TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-41.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
3. Ramirez JA. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med. 2005;26(6):543-52.
4. Aliberti S, Blasi F, Zanaboni AM, et al. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2010;36:128-34.
5. Menendez T, Torres A, Rodriguez de Castro F, et al. Reaching stability in community- acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis. 2004;39:1783-90.
6. File Jr TM. Clinical efficacy of newer agents in short-duration therapy for community- acquired pneumonia. Clin Infect Dis. 2004;39:S159-64.
7. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452-7.
8. Christ-Cain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007;30:556-73.
9. Schuetz P, Muller B, Christ-Cain M et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systemic Reviews 2012, Issue 9. Art. No.: CD007498. doi: 10.1002/14651858.CD007498.pub2.
10. Metlay JP, Atlas SJ, Borowsky LH, et al. Time course of symptom resolution in patients with community acquired pneumonia. Respir Med. 1998;92:1137-42.
11. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(13):1841-54.
12. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120:783-90.
13. Choudhury G, Mandal P, Singanayagam A, et al. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia- a propensity-adjusted analysis. Clin Microbiol Infect. 2011;17:1852-8. This is the only study which evaluates shorter course therapy in severe CAP and confirms efficacy.
14. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000-8.
15. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3):601-7.
16. Christ-Cain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster- randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600-7.
17. Christ-Cain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84-93.
18. Schuetz P, Christ-Cain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs. standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059- 66. This study illustrates that PCT guidance reduced antibiotic exposure and was non-inferior to standard clinical practice guidelines.
19. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin- guided antibiotic therapy in lower respiratory tract infections in «real life»: an international, multicenter poststudy survey ProREAL. Arch Intern Med. 2012;172(9):715-22.
20. Schuetz P, Briel M, Christ-Cain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(5):651-62. This study is a meta-analysis demonstrating the useful of PCT guidance in significantly decreasing antibiotic exposure without increasing mortality risk or treatment failure.
21. Ramirez JA, Vargas S, Ritter G, et al. Early switch from intravenous to oral antibiotics and early hospital discharge. Arch Intern Med. 1999;159:2449-54.
22. Mertz D, Koller M, Haller P, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009;64:188-99.
23. Carratala J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia. Arch Intern Med. 2012;172(12):922-8. This study provides a checklist confirming when early switch from intravenous to oral antibiotic therapy is appropriate.
24. Kozma CM, Dickson M, Raut MK, et al. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP). J Med Econ. 2010;13(4):719-27.
25. Avdic E, Cushinotto LA, Hughes AH, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012;54(11):1581-7. This study illustrates the great impact antimicrobial stewardship teams can have on patient outcomes.